ArticleHepatology communications2023

Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.

Regino P Gonzalez-Peralta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.